Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.
Verhamme KM, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MC, Artibani W, Begaud B, Berges R, Borkowski A, Chappel CR, Costello A, Dobronski P, Farmer RD, Jiménez Cruz F, Jonas U, MacRae K, Pientka L, Rutten FF, van Schayck CP, Speakman MJ, Sturkenboom MC, Tiellac P, Tubaro A, Vallencien G, Vela Navarrete R; Triumph Pan European Expert Panel. Verhamme KM, et al. Among authors: speakman mj. Eur Urol. 2002 Oct;42(4):323-8. doi: 10.1016/s0302-2838(02)00354-8. Eur Urol. 2002. PMID: 12361895
Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Schulman CC, et al. Among authors: speakman mj. Eur Urol. 1996;29(2):145-54. Eur Urol. 1996. PMID: 8647140 Clinical Trial.
Tamsulosin: 3-year long-term efficacy and safety in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction: analysis of a European, multinational, multicenter, open-label study. European Tamsulosin Study Group.
Schulman CC, Cortvriend J, Jonas U, Lock TM, Vaage S, Speakman MJ. Schulman CC, et al. Among authors: speakman mj. Eur Urol. 1999 Dec;36(6):609-20. doi: 10.1159/000020056. Eur Urol. 1999. PMID: 10559616 Clinical Trial.
Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.
Lowe FC, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, O'Leary M, Perez M, Speakman M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H. Lowe FC, et al. Prostate Cancer Prostatic Dis. 2005;8(3):206-9. doi: 10.1038/sj.pcan.4500806. Prostate Cancer Prostatic Dis. 2005. PMID: 15953934
Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise.
Speakman M, Batista J, Berges R, Chartier-Kastler E, Conti G, Desgrandchamps F, Dreikorn K, Lowe F, O'Leary M, Perez M, Trachtenberg J, Tubaro A, Meesen B, Smets L, Stoevelaar H. Speakman M, et al. Prostate Cancer Prostatic Dis. 2005;8(4):369-74. doi: 10.1038/sj.pcan.4500827. Prostate Cancer Prostatic Dis. 2005. PMID: 16130013
Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, Speakman M, Traudtner K, Drake MJ; NEPTUNE Study Group. van Kerrebroeck P, et al. Among authors: speakman m. Eur Urol. 2013 Dec;64(6):1003-12. doi: 10.1016/j.eururo.2013.07.034. Epub 2013 Aug 3. Eur Urol. 2013. PMID: 23932438 Clinical Trial.
91 results